Piramal Pharma Limited Strengthens Portfolio with Yapan Bio Acquisition

Piramal Pharma Limited Expands Biologics Portfolio Through Yapan Bio Acquisition

Piramal Pharma Limited, a prominent name in the pharmaceutical industry, recently announced a significant milestone in its growth strategy. On August 18, 2026, the company revealed the completion of its acquisition of an additional 40.67% stake in Yapan Bio Private Limited. This strategic move transitions Yapan Bio from being an associate to a subsidiary of Piramal Pharma, significantly enhancing the latter's footprint in the biologics sector.

Key Details of the Acquisition

The acquisition, finalized for ₹76 crore (approximately $7.95 million USD), brings Piramal's total ownership of Yapan Bio to 74%. This transformation enables Piramal Pharma to fully integrate Yapan Bio's advanced capabilities into its operations, particularly in the field of complex biologics development and manufacturing. Yapan Bio, located in Hyderabad, specializes in process development and GMP manufacturing services for vaccines and biologics, positioning Piramal to offer a comprehensive suite of services in this domain.

Peter DeYoung, the CEO of Piramal Global Pharma, emphasized the strategic importance of this acquisition, stating, "This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action." By incorporating Yapan Bio's specialized expertise into its global network, Piramal aims to meet the soaring demand for complex biologics and ensure patients worldwide have sustained access to necessary therapies.

Benefits to Piramal Pharma’s Service Offering

The acquisition significantly enhances Piramal Pharma's capabilities, particularly in terms of offering integrated large molecule Contract Development and Manufacturing Organization (CDMO) services. Yapan Bio directly supports the ADCelerate™ platform, which is designed to streamline the development of Antibody-Drug Conjugates (ADCs). This allows for faster transitions from research and development to GMP production, ensuring that life-saving therapies reach the market more efficiently.

Piramal Pharma Solutions (PPS), the company's CDMO arm, will continue to oversee the operations of Yapan Bio. This alignment fosters an environment where advanced large molecule capabilities are seamlessly integrated into Piramal's service offerings, enabling the company to develop and scale complex biologic therapies more effectively.

Broader Impact on the Biologics Market

This acquisition is aligned with Piramal's long-term vision to expand its operations in the biologics sector. The global demand for biologics has been increasing, and this strategic investment positions Piramal to capitalize on this trend. By enhancing its capabilities and resources through Yapan Bio, Piramal is poised to play a pivotal role in the development of future biologic therapies, which are critical in treating various health conditions.

The comprehensive service network, which spans North America, Europe, and Asia, ensures that Piramal can deliver end-to-end solutions throughout the drug lifecycle. With specialized services, including the formulation and manufacture of highly potent APIs and biologics like vaccines and gene therapies, Piramal Pharma is well-equipped to meet the evolving needs of its clients and the healthcare market.

Conclusion

In summary, the acquisition of Yapan Bio by Piramal Pharma Limited marks a significant advancement in the company's strategy to enhance its biologics capabilities. By leveraging Yapan Bio's strengths, Piramal Pharma is not only expanding its service offerings but also fulfilling a critical demand in the global healthcare landscape. This strategic acquisition highlights Piramal's commitment to patient-centric growth and underscores its role as a leader in the pharmaceutical industry.